Key facts
- It has raised $8.3M.
- Notable investors include Osaka University Venture Capital, The Senshu Ikeda Bank, Kiyo Capital Management, Medtech Actuator, Teikoku Pharma USA — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for PaMeLa
- ·The full record, as it builds
Funding rounds
No funding rounds for PaMeLa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PaMeLa
Developer of a pain measurement technology designed to quantitatively measure the pain of patients. The company's technology assists in objectively measuring the intensity of pain based on clinical experiences and research results to replace the current method of subjective evaluation of pain, enabling healthcare professionals to control the pain experienced by their patients and determine the appropriate amount of medicine to be given.
- Sector
- Healthcare
- HQ
- Osaka, Japan
- Founded
- 2016
- Employees
- 8
- Website
- pain-ml.com/
- Ownership
- Privately Held (backing)
PaMeLa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PaMeLa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PaMeLa in its N-PORT filings yet. We sweep new filings monthly.